You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series
|
|---|---|
| Published in |
BMC Pulmonary Medicine, November 2016
|
| DOI | 10.1186/s12890-016-0308-z |
| Pubmed ID | |
| Authors |
Isabelle Delanote, Wim A. Wuyts, Jonas Yserbyt, Eric K. Verbeken, Geert M. Verleden, Robin Vos |
| Abstract |
Following recent approval of pirfenidone and nintedanib for idiopathic pulmonary fibrosis (IPF), questions arise about the use of these antifibrotics in patients awaiting lung transplantation (LTx). Safety and efficacy of antifibrotic drugs in IPF patients undergoing LTx were investigated in a single-centre retrospective cohort analysis. A total of nine patients, receiving antifibrotic therapy for 419 ± 315 days until subsequent LTx, were included. No major side effects were noted. Significant weight loss occurred during antifibrotic treatment (p = 0.0062). FVC tended to stabilize after 12 weeks of treatment in most patients. A moderate decline in FVC, TLC and DLCO was noted during the whole pretransplant time period of antifibrotic therapy. Functional exercise capacity and lung allocation score remained unchanged. No post-operative thoracic wound healing problems, nor severe early anastomotic airway complications were attributable to prior antifibrotic treatment. None of the patients developed chronic lung allograft dysfunction after a median follow-up of 19.8 (11.2-26.5) months; and post-transplant survival was 100% after 1 year and 80% after 2 years. Antifibrotic drugs can probably be safely administered in IPF patients, possibly attenuating disease progression over time, while awaiting LTx. |
X Demographics
The data shown below were collected from the profiles of 35 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 7 | 20% |
| India | 3 | 9% |
| United States | 3 | 9% |
| Canada | 3 | 9% |
| Venezuela, Bolivarian Republic of | 2 | 6% |
| Brazil | 1 | 3% |
| Netherlands | 1 | 3% |
| Argentina | 1 | 3% |
| Mexico | 1 | 3% |
| Other | 3 | 9% |
| Unknown | 10 | 29% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 23 | 66% |
| Practitioners (doctors, other healthcare professionals) | 10 | 29% |
| Scientists | 2 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 56 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 56 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 7 | 13% |
| Student > Bachelor | 7 | 13% |
| Student > Postgraduate | 6 | 11% |
| Researcher | 5 | 9% |
| Student > Master | 5 | 9% |
| Other | 12 | 21% |
| Unknown | 14 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 41% |
| Nursing and Health Professions | 5 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Business, Management and Accounting | 1 | 2% |
| Biochemistry, Genetics and Molecular Biology | 1 | 2% |
| Other | 5 | 9% |
| Unknown | 18 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 31. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 February 2019.
All research outputs
#1,225,812
of 24,903,209 outputs
Outputs from BMC Pulmonary Medicine
#43
of 2,194 outputs
Outputs of similar age
#24,953
of 427,096 outputs
Outputs of similar age from BMC Pulmonary Medicine
#2
of 33 outputs
Altmetric has tracked 24,903,209 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,194 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 427,096 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.